Please assess the completion status of the following clinical trial:

Trial Title: HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Patient with follicular lymphoma grade 1 - 2~* Refractory to rituximab given as monotherapy or in combination with any chemotherapy or to rituximab given as maintenance treatment following R-chemo, defined as:~* failure to achieve at least PR to rituximab given as monotherapy or in combination with any chemotherapy; or,~* disease progression while on rituximab (either given as monotherapy or in combination with any chemotherapy or during rituximab maintenance treatment following R-chemo); or,~* disease progression in responders within 6 months of the last dose of rituximab (either given as monotherapy or in combination with any chemotherapy or after rituximab maintenance treatment schedule following R-chemo)~* Tumor verified to be CD20+ positive from excisional lymph node biopsy~* CT scan in screening phase (based on local evaluation) showing:~* 2 or more clearly demarcated lesions with a largest diameter ≥ 1.5 cm, or~* 1 clearly demarcated lesion with a largest diameter ≥ 2,0 cm~* ECOG Performance Status of 0, 1, or 2~* Age ≥ 18 years~* Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out~Exclusion Criteria~* Previous autologous stem cell transplantation within 6 months~* Previous allogeneic stem cell transplantation~* More than 1 previous radio immunotherapy regimen~* Received radio immunotherapy within 3 months~* Received any Anti-cancer treatment within 4 weeks~* Received monoclonal antibodies, other than rituximab within 3 months~* Patients previously treated with anti-CD20 monoclonal antibodies, other than rituximab~* Life expectancy less than 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).